Investor Relations

Company Overview

We aspire to be the leading healthcare company focused on innovative treatments for women’s health and prostate cancer designed to improve the lives of millions. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer.

Our lead investigational drug candidate is relugolix, a small molecule, GnRH receptor antagonist. We have three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 & 2), two in women with endometriosis-associated pain (SPIRIT 1 & 2), and one in men with advanced prostate cancer (HERO). We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, as a potential treatment for women undergoing assisted reproduction, such as in vitro fertilization (IVF).

Takeda Pharmaceuticals International AG has granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide. Over time, we intend to expand our development pipeline to include other potential treatments for women's health and prostate cancer.

Copyright West LLC. Share price minimum 15 minutes delayed. Market cap from previous market close.

Press Releases
August 20, 2019
Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 2 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
August 6, 2019
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for First Fiscal Quarter Ended June 30, 2019
July 23, 2019
Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and Positive Results from Bioequivalence Study
Jul 23, 2019 at 8:30 AM EDT
LIBERTY 2 Phase 3 Uterine Fibroid and Bioequivalence Study Results
Jun 11, 2019 at 5:40 PM EDT
Goldman Sachs 40th Annual Global Healthcare Conference

SEC Filings

Filing date Description Form View

Quarterly report which provides a continuing view of a company's financial position


Annual report which provides a comprehensive overview of the company for the past year